SGMT vs. RPTX, INCR, SYRS, PDSB, AMLX, CRVO, RNAC, COYA, KPTI, and NVCT
Should you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include Repare Therapeutics (RPTX), InterCure (INCR), Syros Pharmaceuticals (SYRS), PDS Biotechnology (PDSB), Amylyx Pharmaceuticals (AMLX), CervoMed (CRVO), Cartesian Therapeutics (RNAC), Coya Therapeutics (COYA), Karyopharm Therapeutics (KPTI), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical preparations" industry.
Sagimet Biosciences (NASDAQ:SGMT) and Repare Therapeutics (NASDAQ:RPTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.
Sagimet Biosciences has higher earnings, but lower revenue than Repare Therapeutics.
Sagimet Biosciences presently has a consensus price target of $39.60, suggesting a potential upside of 791.89%. Repare Therapeutics has a consensus price target of $17.33, suggesting a potential upside of 395.24%. Given Sagimet Biosciences' higher possible upside, analysts clearly believe Sagimet Biosciences is more favorable than Repare Therapeutics.
In the previous week, Repare Therapeutics had 1 more articles in the media than Sagimet Biosciences. MarketBeat recorded 9 mentions for Repare Therapeutics and 8 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.79 beat Repare Therapeutics' score of 0.70 indicating that Sagimet Biosciences is being referred to more favorably in the media.
Repare Therapeutics received 22 more outperform votes than Sagimet Biosciences when rated by MarketBeat users. However, 100.00% of users gave Sagimet Biosciences an outperform vote while only 60.71% of users gave Repare Therapeutics an outperform vote.
Sagimet Biosciences has a net margin of 0.00% compared to Repare Therapeutics' net margin of -46.69%. Sagimet Biosciences' return on equity of 0.00% beat Repare Therapeutics' return on equity.
87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 85.1% of Repare Therapeutics shares are owned by institutional investors. 17.6% of Sagimet Biosciences shares are owned by insiders. Comparatively, 28.5% of Repare Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Sagimet Biosciences beats Repare Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Sagimet Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sagimet Biosciences Competitors List
Related Companies and Tools
